Fuso Pharmaceutical Industries,Ltd.
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Fuso Pharmaceutical Industries,Ltd. owes ¥0.61 for every ¥1 it owns. Fuso Pharmaceutical Industries,Ltd. returned to profit in the year to Mar 2026, after a loss the year before.
Compared with Healthcare companies in Japan · latest annual results Mar 2026.
P/E ratio
8.2Investors pay ¥8.2 for every ¥1 of Fuso Pharmaceutical Industries,Ltd.'s yearly profit, lower than 93% of Healthcare companies in Japan.
P/B ratio
0.51The share price is 0.51 times Fuso Pharmaceutical Industries,Ltd.'s book value per share, lower than 96% of Healthcare companies in Japan.
Market cap
¥17.9 BThe total market value of all of Fuso Pharmaceutical Industries,Ltd.'s shares at today's price (share price × number of shares), larger than 51% of Healthcare companies in Japan. PosiCap size class: Mini Cap.
Net worth (book value)
¥35.1 BWhat Fuso Pharmaceutical Industries,Ltd. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
¥4,107Net worth divided by the number of shares. The share price of ¥2,093 is 0.5 times this, which is the P/B above.
Return on equity (ROE)
6.4%Fuso Pharmaceutical Industries,Ltd. earned 6.4% on its shareholders' money over the last year, lower than 56% of Healthcare companies in Japan.
Owes vs Owns
0.61×Fuso Pharmaceutical Industries,Ltd. owes ¥0.61 for every ¥1 it owns (moderate).
Dividend yield
4.28%Fuso Pharmaceutical Industries,Ltd. pays 4.28% of its share price as dividends a year, higher than 89% of dividend-paying Healthcare companies in Japan.
Revenue growth
+3%Revenue rose 3% in the year to Mar 2026, and grew 7% a year on average over 3 years.
Profit growth
Back to profitFuso Pharmaceutical Industries,Ltd. returned to profit in the year to Mar 2026, after a loss the year before.
Profit margin
3.2%Fuso Pharmaceutical Industries,Ltd. keeps ¥3 of every ¥100 of revenue as net profit.
Cash quality
-3.1×Cash from Fuso Pharmaceutical Industries,Ltd.'s business was -3.1× its reported profit in the year to Mar 2026 — the business used cash even though it reported a profit.
Interest cover
8.0×Fuso Pharmaceutical Industries,Ltd.'s operating profit covered its interest costs 8.0 times in the year to Mar 2026.
Cash vs debt
Net debtFuso Pharmaceutical Industries,Ltd. had ¥23.6 B more debt than cash (net debt) at Mar 2026.
Questions
What is Fuso Pharmaceutical Industries,Ltd.'s P/E ratio?
Investors pay ¥8.2 for every ¥1 of Fuso Pharmaceutical Industries,Ltd.'s yearly profit, lower than 93% of Healthcare companies in Japan.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Fuso Pharmaceutical Industries,Ltd.: ¥17.9 B ÷ ¥35.1 B (31 Mar 2026) = 0.5.
What is Fuso Pharmaceutical Industries,Ltd.'s return on equity?
Fuso Pharmaceutical Industries,Ltd. earned 6.4% on its shareholders' money over the last year, lower than 56% of Healthcare companies in Japan.
How much does Fuso Pharmaceutical Industries,Ltd. owe compared with what it owns?
Fuso Pharmaceutical Industries,Ltd. owes ¥0.61 for every ¥1 it owns (moderate).
Does Fuso Pharmaceutical Industries,Ltd. pay a dividend?
Yes. Fuso Pharmaceutical Industries,Ltd. pays 4.28% of its share price as dividends a year, higher than 89% of dividend-paying Healthcare companies in Japan.
Is Fuso Pharmaceutical Industries,Ltd.'s revenue growing?
Revenue rose 3% in the year to Mar 2026, and grew 7% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.